Fluoxetine Protects Retinal Ischemic Damage in Mice

Background: To evaluate the neuroprotective effect of the topical ocular administration of fluoxetine (FLX) in a mouse model of acute retinal damage. Methods: Ocular ischemia/reperfusion (I/R) injury in C57BL/6J mice was used to elicit retinal damage. Mice were divided into three groups: control group, I/R group, and I/R group treated with topical FLX. A pattern electroretinogram (PERG) was used as a sensitive measure of retinal ganglion cell (RGC) function. Finally, we analyzed the retinal mRNA expression of inflammatory markers (IL-6, TNF-α, Iba-1, IL-1β, and S100β) through Digital Droplet PCR. Results: PERG amplitude values were significantly (p < 0.05) higher in the I/R-FLX group compared to the I/R group, whereas PERG latency values were significantly (p < 0.05) reduced in I/R-FLX-treated mice compared to the I/R group. Retinal inflammatory markers increased significantly (p < 0.05) after I/R injury. FLX treatment was able to significantly (p < 0.05) attenuate the expression of inflammatory markers after I/R damage. Conclusions: Topical treatment with FLX was effective in counteracting the damage of RGCs and preserving retinal function. Moreover, FLX treatment attenuates the production of pro-inflammatory molecules elicited by retinal I/R damage. Further studies need to be performed to support the use of FLX as neuroprotective agent in retinal degenerative diseases.

[1]  A. Grumezescu,et al.  An Overview of Oxidative Stress, Neuroinflammation, and Neurodegenerative Diseases , 2022, International journal of molecular sciences.

[2]  V. Uskoković,et al.  Brain-Derived Neurotrophic Factor-Mediated Neuroprotection in Glaucoma: A Review of Current State of the Art , 2022, Frontiers in Pharmacology.

[3]  M. Plebanski,et al.  Targeting Differential Roles of Tumor Necrosis Factor Receptors as a Therapeutic Strategy for Glaucoma , 2022, Frontiers in Immunology.

[4]  Y. Cai,et al.  Microglia in the Neuroinflammatory Pathogenesis of Alzheimer’s Disease and Related Therapeutic Targets , 2022, Frontiers in Immunology.

[5]  K. Jonak,et al.  Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study , 2022, Frontiers in Pharmacology.

[6]  David J. Calkins,et al.  Solving neurodegeneration: common mechanisms and strategies for new treatments , 2022, Molecular Neurodegeneration.

[7]  James F. Everson,et al.  Modulation of microglial activation by antidepressants , 2022, Journal of psychopharmacology.

[8]  R. Casson Medical therapy for glaucoma: A review , 2022, Clinical & experimental ophthalmology.

[9]  S. Salomone,et al.  Antioxidant Activity of Fluoxetine and Vortioxetine in a Non-Transgenic Animal Model of Alzheimer’s Disease , 2021, Frontiers in Pharmacology.

[10]  R. Maccarone,et al.  Retinal ganglion cell loss in an ex vivo mouse model of optic nerve cut is prevented by curcumin treatment , 2021, Cell death discovery.

[11]  Osama M. Ahmed,et al.  A Review of Potential Novel Glaucoma Therapeutic Options Independent of Intraocular Pressure. , 2021, Survey of ophthalmology.

[12]  C. Tovilla-Zárate,et al.  Fluoxetine modulates the pro-inflammatory process of IL-6, IL-1β and TNF-α levels in individuals with depression: a systematic review and meta-analysis , 2021, Psychiatry Research.

[13]  Takaaki Kuwajima,et al.  Serotonin transporter-mediated molecular axis regulates regional retinal ganglion cell vulnerability and axon regeneration after nerve injury , 2021, PLoS genetics.

[14]  F. Drago,et al.  Health Technology Assessment of Advanced Therapy Medicinal Products: Comparison Among 3 European Countries , 2021, Frontiers in Pharmacology.

[15]  A. Pascale,et al.  Ocular Neurodegenerative Diseases: Interconnection between Retina and Cortical Areas , 2021, Cells.

[16]  N. Vale,et al.  Antidepressants in Alzheimer’s Disease: A Focus on the Role of Mirtazapine , 2021, Pharmaceuticals.

[17]  E. Strettoi,et al.  Lipid Nanoparticles Traverse Non-Corneal Path to Reach the Posterior Eye Segment: In Vivo Evidence , 2021, Molecules.

[18]  F. Oddone,et al.  Risk Factors for Retinal Ganglion Cell Distress in Glaucoma and Neuroprotective Potential Intervention , 2021, International journal of molecular sciences.

[19]  F. Drago,et al.  Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage , 2021, Frontiers in Pharmacology.

[20]  Patrice D Smith,et al.  Harnessing Astrocytes and Müller Glial Cells in the Retina for Survival and Regeneration of Retinal Ganglion Cells , 2021, Cells.

[21]  J. Mollon,et al.  Retinal Ganglion Cells—Diversity of Cell Types and Clinical Relevance , 2021, Frontiers in Neurology.

[22]  F. Drago,et al.  Influence of Trace Elements on Neurodegenerative Diseases of The Eye—The Glaucoma Model , 2021, International journal of molecular sciences.

[23]  A. Ponzetto,et al.  The Role of Neuroinflammation in Glaucoma: An Update on Molecular Mechanisms and New Therapeutic Options , 2021, Frontiers in Neurology.

[24]  Mohamed Said Boulkrane,et al.  COVID-19 Disease and Vitamin D: A Mini-Review , 2020, Frontiers in Pharmacology.

[25]  G. Guidoboni,et al.  Neurodegenerative Disorders of the Eye and of the Brain: A Perspective on Their Fluid-Dynamical Connections and the Potential of Mechanism-Driven Modeling , 2020, Frontiers in Neuroscience.

[26]  C. Baudouin,et al.  Inflammation in Glaucoma: From the back to the front of the eye, and beyond , 2020, Progress in Retinal and Eye Research.

[27]  F. Jessen,et al.  Depression—an underrecognized target for prevention of dementia in Alzheimer’s disease , 2020, Translational Psychiatry.

[28]  Jian Liu,et al.  Neuroprotective Effects of Fluoxetine Against Chronic Stress-Induced Neural Inflammation and Apoptosis: Involvement of the p38 Activity , 2020, Frontiers in Physiology.

[29]  B. Kiss,et al.  Redox metabolism modulation as a mechanism in SSRI toxicity and pharmacological effects , 2020, Archives of Toxicology.

[30]  A. Ambrósio,et al.  Neuroprotective Strategies for Retinal Ganglion Cell Degeneration: Current Status and Challenges Ahead , 2020, International journal of molecular sciences.

[31]  John H. Zhang,et al.  Glial Cells: Role of the Immune Response in Ischemic Stroke , 2020, Frontiers in Immunology.

[32]  N. Greig,et al.  Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments , 2019, Front. Cell Dev. Biol..

[33]  Mouse Model , 2019, Definitions.

[34]  S. Chavala,et al.  Hybrid Compound SA-2 is Neuroprotective in Animal Models of Retinal Ganglion Cell Death. , 2019, Investigative ophthalmology & visual science.

[35]  A. Palmeri,et al.  Fluoxetine and Vortioxetine Reverse Depressive-Like Phenotype and Memory Deficits Induced by Aβ1-42 Oligomers in Mice: A Key Role of Transforming Growth Factor-β1 , 2019, Front. Pharmacol..

[36]  D. Zacks,et al.  Retinal neuroprotection: current strategies and future directions , 2019, Current opinion in ophthalmology.

[37]  W. Cubała,et al.  The Influence of Antidepressants on the Immune System , 2019, Archivum Immunologiae et Therapiae Experimentalis.

[38]  F. Shi,et al.  Dissemination of brain inflammation in traumatic brain injury , 2019, Cellular & Molecular Immunology.

[39]  B. Jin,et al.  Norfluoxetine Prevents Degeneration of Dopamine Neurons by Inhibiting Microglia-Derived Oxidative Stress in an MPTP Mouse Model of Parkinson's Disease , 2018, Mediators of inflammation.

[40]  Xinghuai Sun,et al.  Activation of 5-HT1A Receptors Promotes Retinal Ganglion Cell Function by Inhibiting the cAMP-PKA Pathway to Modulate Presynaptic GABA Release in Chronic Glaucoma , 2018, The Journal of Neuroscience.

[41]  M. Craske,et al.  The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation , 2018, Neuroscience & Biobehavioral Reviews.

[42]  Machelle T. Pardue,et al.  Neuroprotective strategies for retinal disease , 2018, Progress in Retinal and Eye Research.

[43]  C. Nucci,et al.  Neuroprotective agents in the management of glaucoma , 2018, Eye.

[44]  V. Yarnykh,et al.  Effects of Fluoxetine on Hippocampal Neurogenesis and Neuroprotection in the Model of Global Cerebral Ischemia in Rats , 2018, International journal of molecular sciences.

[45]  V. Porciatti,et al.  Anesthetic Preconditioning as Endogenous Neuroprotection in Glaucoma , 2018, International journal of molecular sciences.

[46]  M. Carbonelli,et al.  Patterns of Retinal Ganglion Cell Damage in Neurodegenerative Disorders: Parvocellular vs Magnocellular Degeneration in Optical Coherence Tomography Studies , 2017, Front. Neurol..

[47]  M. Wagner,et al.  Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer's Dementia in Individuals With Previous Depression. , 2017, The American journal of psychiatry.

[48]  L. Levin,et al.  Neuroprotection in Glaucoma: Animal Models and Clinical Trials. , 2017, Annual review of vision science.

[49]  Jian-Zhi Wang,et al.  Long-term Ameliorative Effects of the Antidepressant Fluoxetine Exposure on Cognitive Deficits in 3 × TgAD Mice , 2016, Molecular Neurobiology.

[50]  F. Grus,et al.  Modulation of the Immune System for the Treatment of Glaucoma , 2017, Current neuropharmacology.

[51]  F. K. Ludka,et al.  Atorvastatin and Fluoxetine Prevent Oxidative Stress and Mitochondrial Dysfunction Evoked by Glutamate Toxicity in Hippocampal Slices , 2017, Molecular Neurobiology.

[52]  London,et al.  European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options. , 2017, The British journal of ophthalmology.

[53]  P. Gass,et al.  Fluoxetine reverses behavior changes in socially isolated rats: role of the hippocampal GSH-dependent defense system and proinflammatory cytokines , 2017, European Archives of Psychiatry and Clinical Neuroscience.

[54]  Pete A. Williams,et al.  Neuroinflammation in glaucoma: A new opportunity , 2017, Experimental eye research.

[55]  Karan H. Patel,et al.  Serotonin receptor 2C regulates neurite growth and is necessary for normal retinal processing of visual information , 2017, Developmental neurobiology.

[56]  Jiawei Wang,et al.  Melanopsin-Containing or Non-Melanopsin-Containing Retinal Ganglion Cells Response to Acute Ocular Hypertension With or Without Brain-Derived Neurotrophic Factor Neuroprotection. , 2016, Investigative ophthalmology & visual science.

[57]  J. Jonas,et al.  MicroRNA regulation in an animal model of acute ocular hypertension , 2016, Acta ophthalmologica.

[58]  Gang Hu,et al.  Fluoxetine protects against IL-1β-induced neuronal apoptosis via downregulation of p53 , 2016, Neuropharmacology.

[59]  E. Duh,et al.  A Mouse Model of Retinal Ischemia-Reperfusion Injury Through Elevation of Intraocular Pressure. , 2016, Journal of visualized experiments : JoVE.

[60]  Y. Tizabi Duality of Antidepressants and Neuroprotectants , 2016, Neurotoxicity Research.

[61]  T. Jeitner,et al.  Serotonin as a putative scavenger of hypohalous acid in the brain. , 2016, Biochimica et biophysica acta.

[62]  E. Lauterbach Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. , 2016, American journal of neurodegenerative disease.

[63]  G. Sancesario,et al.  Association Between Alzheimer's Disease and Glaucoma: A Study Based on Heidelberg Retinal Tomography and Frequency Doubling Technology Perimetry , 2015, Front. Neurosci..

[64]  V. Porciatti Electrophysiological assessment of retinal ganglion cell function. , 2015, Experimental eye research.

[65]  F. Drago,et al.  Neuroprotective effects of the monoamine oxidase inhibitor tranylcypromine and its amide derivatives against Aβ(1-42)-induced toxicity. , 2015, European journal of pharmacology.

[66]  J. Krakauer,et al.  Fluoxetine Maintains a State of Heightened Responsiveness to Motor Training Early After Stroke in a Mouse Model , 2015, Stroke.

[67]  C. Trentini,et al.  The efficacy of long-term psychodynamic psychotherapy, fluoxetine and their combination in the outpatient treatment of depression , 2015, Psychotherapy research : journal of the Society for Psychotherapy Research.

[68]  Xuan Sun,et al.  Fluoxetine enhanced neurogenesis is not translated to functional outcome in stroke rats , 2015, Neuroscience Letters.

[69]  L. Probert TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects , 2015, Neuroscience.

[70]  A. Corbett,et al.  Increasing neurogenesis with fluoxetine, simvastatin and ascorbic Acid leads to functional recovery in ischemic stroke. , 2015, Recent patents on drug delivery & formulation.

[71]  Katsunori Kobayashi,et al.  Role of the 5-HT4 receptor in chronic fluoxetine treatment-induced neurogenic activity and granule cell dematuration in the dentate gyrus , 2015, Molecular Brain.

[72]  T. Yune,et al.  Fluoxetine prevents oligodendrocyte cell death by inhibiting microglia activation after spinal cord injury. , 2015, Journal of neurotrauma.

[73]  A. Aref,et al.  Senile Dementia and Glaucoma: Evidence for a Common Link , 2015, Journal of ophthalmic & vision research.

[74]  M. Vidal-Sanz,et al.  BDNF Rescues RGCs But Not Intrinsically Photosensitive RGCs in Ocular Hypertensive Albino Rat Retinas. , 2015, Investigative ophthalmology & visual science.

[75]  J. Morris,et al.  Reply to comment on “An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice” , 2014, Science Translational Medicine.

[76]  Haiyun Xu,et al.  Fluoxetine improves behavioral performance by suppressing the production of soluble β-amyloid in APP/PS1 mice. , 2014, Current Alzheimer research.

[77]  V. Porciatti,et al.  Transgenic mice expressing mutated Tyr437His human myocilin develop progressive loss of retinal ganglion cell electrical responsiveness and axonopathy with normal iop. , 2014, Investigative ophthalmology & visual science.

[78]  Onkar S. Dhande,et al.  Retinal ganglion cell maps in the brain: implications for visual processing , 2014, Current Opinion in Neurobiology.

[79]  M. V. Cicinelli,et al.  Low levels of 17-β-oestradiol, oestrone and testosterone correlate with severe evaporative dysfunctional tear syndrome in postmenopausal women: a case–control study , 2014, British Journal of Ophthalmology.

[80]  Woosuk Kim,et al.  Antidepressants for neuro-regeneration: from depression to Alzheimer’s disease , 2013, Archives of pharmacal research.

[81]  Xiang Yang Zhang,et al.  Free radicals, antioxidant defense systems, and schizophrenia , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[82]  R. Vohra,et al.  The role of inflammation in the pathogenesis of glaucoma. , 2013, Survey of ophthalmology.

[83]  J. Hošek,et al.  TNF-α signalling and inflammation: interactions between old acquaintances , 2013, Inflammation Research.

[84]  Lori M. Ventura,et al.  Progressive loss of retinal ganglion cell function precedes structural loss by several years in glaucoma suspects. , 2013, Investigative ophthalmology & visual science.

[85]  G. Tezel Immune regulation toward immunomodulation for neuroprotection in glaucoma. , 2013, Current opinion in pharmacology.

[86]  B. Frey,et al.  Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder , 2012, Oxidative medicine and cellular longevity.

[87]  R. Morishita,et al.  Preclinical Models to Investigate Retinal Ischemia: Advances and Drawbacks , 2012, Front. Neur..

[88]  P. Kaufman,et al.  Advances in glaucoma treatment and management: outflow drugs. , 2012, Investigative ophthalmology & visual science.

[89]  J. Goldberg,et al.  Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. , 2012, Ophthalmology.

[90]  J. Winkler,et al.  Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy , 2012, Experimental Neurology.

[91]  M. Kahook,et al.  Prevalence of Cognitive Impairment, Depression, and Anxiety Symptoms Among Older Adults With Glaucoma , 2012, Journal of glaucoma.

[92]  B. Morquette,et al.  The molecular basis of retinal ganglion cell death in glaucoma , 2012, Progress in Retinal and Eye Research.

[93]  M. Farina,et al.  Ascorbic acid treatment, similarly to fluoxetine, reverses depressive-like behavior and brain oxidative damage induced by chronic unpredictable stress. , 2012, Journal of psychiatric research.

[94]  F. Drago,et al.  Carbon monoxide and the eye: Implications for glaucoma therapy. , 2011, Pharmacology & therapeutics.

[95]  C. Romano,et al.  Agonists at the serotonin receptor (5-HT(1A)) protect the retina from severe photo-oxidative stress. , 2011, Investigative ophthalmology & visual science.

[96]  M. Vidal-Sanz,et al.  Brain derived neurotrophic factor maintains Brn3a expression in axotomized rat retinal ganglion cells. , 2011, Experimental eye research.

[97]  M. Vetter,et al.  Early microglia activation in a mouse model of chronic glaucoma , 2011, The Journal of comparative neurology.

[98]  Sung‐Hwa Yoon,et al.  Fluoxetine prevents LPS-induced degeneration of nigral dopaminergic neurons by inhibiting microglia-mediated oxidative stress , 2010, Brain Research.

[99]  T. Connor,et al.  Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. , 2009, The international journal of neuropsychopharmacology.

[100]  Charles L. Raison,et al.  Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression , 2009, Biological Psychiatry.

[101]  E. Agardh,et al.  Inflammatory Markers in Nondiabetic and Diabetic Rat Retinas Exposed to Ischemia Followed by Reperfusion , 2008, Retina.

[102]  N. Sharif,et al.  Serotonin receptor subtype mRNA expression in human ocular tissues, determined by RT-PCR. , 2006, Molecular vision.

[103]  J. Clark,et al.  What does tumour necrosis factor excess do to the immune system long term? , 2005, Annals of the rheumatic diseases.

[104]  Shaoqing He,et al.  Hypoxia augments TNF-alpha-mediated endothelin-1 release and cell proliferation in human optic nerve head astrocytes. , 2004, Biochemical and biophysical research communications.

[105]  N. Osborne,et al.  Retinal ischemia: mechanisms of damage and potential therapeutic strategies , 2004, Progress in Retinal and Eye Research.

[106]  B. Aggarwal Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.

[107]  D. Goeddel,et al.  TNF-R1 Signaling: A Beautiful Pathway , 2002, Science.

[108]  S. Mohand-Said,et al.  Neurodegenerative and Neuroprotective Effects of Tumor Necrosis Factor (TNF) in Retinal Ischemia: Opposite Roles of TNF Receptor 1 and TNF Receptor 2 , 2002, The Journal of Neuroscience.

[109]  C. Erb,et al.  High Occurrence Rate of Glaucoma among Patients with Alzheimer’s Disease , 2002, European Neurology.

[110]  M. Wax,et al.  TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. , 2001, Investigative ophthalmology & visual science.

[111]  M. Wax,et al.  Increased Production of Tumor Necrosis Factor-a by Glial Cells Exposed to Simulated Ischemia or Elevated Hydrostatic Pressure Induces Apoptosis in Cocultured Retinal Ganglion Cells , 2000 .

[112]  C. Barnstable,et al.  Müller cell protection of rat retinal ganglion cells from glutamate and nitric oxide neurotoxicity. , 2000, Investigative ophthalmology & visual science.

[113]  S M Podos,et al.  Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. , 1996, Archives of ophthalmology.

[114]  Shanshan Zhao,et al.  Neuroplasticity and behavioral effects of fluoxetine after experimental stroke. , 2017, Restorative neurology and neuroscience.

[115]  R. Nickells,et al.  Neuroinflammation in Glaucoma and Optic Nerve Damage. , 2015, Progress in molecular biology and translational science.

[116]  M. Tansey,et al.  TNF: a key neuroinflammatory mediator of neurotoxicity and neurodegeneration in models of Parkinson's disease. , 2011, Advances in experimental medicine and biology.

[117]  M. Zueva,et al.  [Molecular mechanisms of retinal ischemia]. , 2010, Vestnik oftalmologii.

[118]  G. Tezel TNF-alpha signaling in glaucomatous neurodegeneration. , 2008, Progress in brain research.

[119]  R. Dantzer,et al.  From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.

[120]  Haiyun Xu,et al.  Dose-Related Effects of Chronic Antidepressants on Neuroprotective Proteins BDNF, Bcl-2 and Cu/Zn-SOD in Rat Hippocampus , 2003, Neuropsychopharmacology.

[121]  Andreas U Bayer,et al.  Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease. , 2002, American journal of ophthalmology.

[122]  F. Nicoletti,et al.  Mitotic signaling by beta-amyloid causes neuronal death. , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.